Diagnostic issues in liver transplantation pathology

Clinics in Liver Disease

Volumn 6, Issue 2, 2002, Pages 555-570

  Lefkowitch, Jay H ^a  

^a Columbia University ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTERY THROMBOSIS; AUTOIMMUNE HEPATITIS; BILE DUCT OBSTRUCTION; BILIARY CIRRHOSIS; CYTOMEGALOVIRUS; EPSTEIN BARR VIRUS; FATTY LIVER; GRAFT FAILURE; GRAFT REJECTION; HEPATIC ARTERY; HEPATITIS; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HERPES SIMPLEX VIRUS; LIVER TRANSPLANTATION; REPERFUSION INJURY; REVIEW; SCLEROSING CHOLANGITIS; ACUTE DISEASE; CYTOMEGALIC INCLUSION BODY DISEASE; DONOR; HUMAN; LIVER; PATHOLOGY; POSTOPERATIVE COMPLICATION; RECURRENT DISEASE;

ACUTE DISEASE; CYTOMEGALOVIRUS INFECTIONS; GRAFT REJECTION; HEPATITIS, AUTOIMMUNE; HUMAN; LIVER; LIVER TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; RECURRENCE; TISSUE DONORS; HUMANS;

EID: 0036318101     PISSN: 10893261     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1089-3261(02)00003-X     Document Type: Review

References (62)

1. Histopathology of the liver following transplantation
2. Acute hepatic allograft rejection: Incidence, risk factors and impact on outcome
3. Primary graft dysfunction after liver transplantation: From pathogenesis to prevention
4. Risk factors for primary dysfunction after liver transplantation - A multivariate analysis
5. The use of donor fatty liver for liver transplantation: A challenge or a quagmire?
6. Role of hepatocytes and bile duct cells in preservation-reperfusion injury of liver grafts
7. Body mass index as a predictor of hepatic steatosis in living liver donors
8. Thin chance for fat people (to become living donors)
9. Use of livers with microvesicular fat safely expands the donor pool
10. Diffuse hepatocyte ballooning in liver biopsies from orthotopic liver transplant patients
11. Hepatocellular ballooning after liver transplantation: A light and electronmicroscopic study with clinicopathological correlation
12. Complement activation after ischemia-reperfusion in human liver allografts: Incidence and pathophysiological relevance
13. Postreperfusion biopsies are useful in predicting complications after liver transplantation
14. Cholestatic jaundice after hepatic transplantation. A nonimmunologically mediated event
15. Pathology of hepatic transplantation: A review of 62 adult allograft recipients immunosuppressed with a cyclosporine/steroid regimen
16. Chronic rejection after liver transplantation: A study of clinical, histopathological and immunological features
17. Histological findings in liver allograft rejection-new insights into the pathogenesis of hepatocellular damage in liver allografts
18. Banff schema for grading liver allograft rejection: An international consensus document
19. Terminology for hepatic allograft rejection
20. Orthotopic liver transplantation: A pathological study of 63 serial liver biopsies from 17 patients with special reference to the diagnostic features and natural history of rejection
21. Hepatic allograft rejection: New developments in terminology, diagnosis, prevention, and treatment
22. The eosinophil as an effector cell of the immune response during hepatic allograft rejection
23. Eosinophils in acute cellular rejection in liver allografts
24. Current status of FK 506 in liver transplantation
25. Liver-function studies in heart transplant recipients treated with cyclosporin A
26. FK-506 enters the clinic
27. Central venulitis in pediatric liver allografts
28. Central venulitis in liver allografts: Considerations of differential diagnosis
29. Early detection of hepatitis C allograft reinfection after orthotopic liver transplantation: A molecular and histologic study
30. Steatosis in donor and transplant liver biopsies
31. Living related liver transplantation: Histopathologic analysis of graft dysfunction in 304 patients
32. Update of the international Banff schema for liver allograft rejection: Working recommendations for the histopathologic staging and reporting of chronic rejection
33. Atherosclerosis of the liver allograft
34. Development of ductopaenic liver allograft rejection includes a "hepatitic" phase prior to duct loss
35. Fibrous obliterative lesions of veins contribute to progressive fibrosis in chronic liver allograft rejection
36. De novo hepatitis with autoimmune antibodies and atypical histology
37. Live donor liver transplantation
38. Clinical patterns of cytomegalovirus disease after liver transplantation
39. A multivariate analysis of risk factors for cytomegalovirus infection in liver transplant recipients
40. Risk factors for cytomegalovirus and severe bacterial infections following liver transplantation: A prospective multivariate time-dependent analysis
41. Cytomegalovirus hepatitis: A histological and immunohistochemical study
42. Mini-microabscess syndrome in liver transplant patients
43. Early diagnosis of cytomegalovirus hepatitis in liver transplant recipients: Role of immunostaining, DNA hybridization and culture of hepatic tissue
44. Localization of cytomegalovirus antigens in liver allografts over time
45. Recurrent disease after liver transplantation
46. Immunohistochemical detection of HCV in cirrhosis, dysplastic nodules and hepatocellular carcinomas with parallel-tissue quantitative RT-PCR
47. Fibrosing cytolytic liver failure secondary to recurrent hepatitis B after liver transplantation
48. Case records of the Massachusetts General Hospital Case 2-2000
49. Fibrosing cholestatic hepatitis in a hepatitis B surface antigen carrier after renal transplantation
50. Hepatic histological findings after transplantation for chronic hepatitis B virus infection, including a unique pattern of fibrosing cholestatic hepatitis
51. Fibrosing cholestatic hepatitis in renal transplant recipients with hepatitis C virus infection
52. Fibrosing cholestatic hepatitis in a transplant recipient with hepatitis B virus precore mutant
53. High-level expression of hepatitis B viral antigens in fibrosing cholestatic hepatitis
54. Recurrence of hepatitis B and delta hepatitis after orthotopic liver transplantation
55. Increased hepatocyte expression of hepatitis B virus transcription in patients with features of fibrosing cholestatic hepatitis
56. Hepatitis B virus reinfection after orthotopic liver transplantation. Serological and clinical implications
57. Post-transplant recurrent hepatitis B viral liver disease. Viral-burden, steatoviral, and fibroviral hepatitis B
58. Hepatitis B virus infection in liver allografts
59. De-novo autoimmune hepatitis after liver transplantation
60. Autoimmune hepatitis as a late complication of liver transplantation
61. Development of autoimmune hepatitis following liver transplantation for primary biliary cirrhosis
62. Concurrent de novo autoimmune hepatitis and recurrence of primary biliary cirrhosis post-liver transplantation